DK1073634T3 - Fremgangsmåde til fremstilling af enantiomerrent N-methyl-N[(1S)-1-phenyl-2-2((3S)-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid - Google Patents

Fremgangsmåde til fremstilling af enantiomerrent N-methyl-N[(1S)-1-phenyl-2-2((3S)-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid

Info

Publication number
DK1073634T3
DK1073634T3 DK99923421T DK99923421T DK1073634T3 DK 1073634 T3 DK1073634 T3 DK 1073634T3 DK 99923421 T DK99923421 T DK 99923421T DK 99923421 T DK99923421 T DK 99923421T DK 1073634 T3 DK1073634 T3 DK 1073634T3
Authority
DK
Denmark
Prior art keywords
diphenylacetamide
hydroxypyrrolidin
phenyl
ethyl
methyl
Prior art date
Application number
DK99923421T
Other languages
Danish (da)
English (en)
Inventor
Andreas Bathe
Bernd Helfert
Ingeborg Stein
Karl-August Ackermann
Rudolf Gottschlich
Jens Budak
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7865063&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1073634(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of DK1073634T3 publication Critical patent/DK1073634T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B35/00—Reactions without formation or introduction of functional groups containing hetero atoms, involving a change in the type of bonding between two carbon atoms already directly linked
    • C07B35/02—Reduction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C07B43/06—Formation or introduction of functional groups containing nitrogen of amide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK99923421T 1998-04-20 1999-04-16 Fremgangsmåde til fremstilling af enantiomerrent N-methyl-N[(1S)-1-phenyl-2-2((3S)-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid DK1073634T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19817393 1998-04-20
DE19827633A DE19827633A1 (de) 1998-04-20 1998-06-20 Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid

Publications (1)

Publication Number Publication Date
DK1073634T3 true DK1073634T3 (da) 2006-01-09

Family

ID=7865063

Family Applications (2)

Application Number Title Priority Date Filing Date
DK99923421T DK1073634T3 (da) 1998-04-20 1999-04-16 Fremgangsmåde til fremstilling af enantiomerrent N-methyl-N[(1S)-1-phenyl-2-2((3S)-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid
DK05016750.1T DK1607090T3 (da) 1998-04-20 1999-04-16 Asimadolin til behandling af irritabel tyktarm (Irritable Bowel Syndrome)

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK05016750.1T DK1607090T3 (da) 1998-04-20 1999-04-16 Asimadolin til behandling af irritabel tyktarm (Irritable Bowel Syndrome)

Country Status (28)

Country Link
US (1) US6344566B1 (ru)
EP (2) EP1607090B1 (ru)
JP (1) JP4688292B2 (ru)
KR (1) KR100649175B1 (ru)
CN (2) CN1846696A (ru)
AR (2) AR019080A1 (ru)
AT (2) ATE303361T1 (ru)
AU (2) AU761721B2 (ru)
BR (1) BR9909731A (ru)
CA (1) CA2329210C (ru)
CY (1) CY1112314T1 (ru)
CZ (1) CZ301121B6 (ru)
DE (2) DE19827633A1 (ru)
DK (2) DK1073634T3 (ru)
ES (2) ES2375384T3 (ru)
HK (1) HK1039111A1 (ru)
HU (1) HUP0101600A3 (ru)
MY (1) MY120471A (ru)
NO (1) NO317984B1 (ru)
PL (1) PL206969B1 (ru)
PT (1) PT1607090E (ru)
RU (1) RU2298549C2 (ru)
SI (2) SI1073634T1 (ru)
SK (2) SK286442B6 (ru)
TW (1) TWI249524B (ru)
UA (1) UA73472C2 (ru)
WO (1) WO1999054298A1 (ru)
ZA (1) ZA200006689B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10259245A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
EP1680115A1 (en) * 2003-10-30 2006-07-19 Tioga Pharmaceuticals, Inc. Use of selective opiate receptor modulators in the treatment of neuropathy
US20070160559A1 (en) * 2006-01-12 2007-07-12 Roszell James A Skin disinfectant composition and methods for using
CN101677997B (zh) * 2007-03-30 2012-05-09 泰奥加制药公司 用于治疗腹泻型和交替型肠易激综合征的κ-阿片剂激动剂
CN103664727A (zh) * 2013-12-19 2014-03-26 无锡万全医药技术有限公司 一种一锅法制备1-[(3s)-3-羟基吡咯烷-1-基]-(2s)-2-甲氨基-2-苯基乙烷的工艺
CN103772257A (zh) * 2013-12-31 2014-05-07 无锡万全医药技术有限公司 一种制备2-((3s)-3-羟基吡咯烷-1-基)-(1s)-1-苯乙基氨基甲酸酯的方法
WO2016161085A1 (en) 2015-04-01 2016-10-06 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
CN112574068A (zh) * 2020-11-17 2021-03-30 万华化学（宁波）有限公司 一种低色号高稳定性碳化二亚胺改性异氰酸酯的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232978A (en) * 1988-12-23 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung 1-(2-arylethyl)-pyrrolidines
DE4034785A1 (de) * 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
DE4215213A1 (de) * 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide
DE4425071C2 (de) * 1994-07-15 1996-08-29 Degussa Verfahren zur Herstellung optisch aktiver Pyrrolidine mit hoher Enantiomerenreinheit
DE19523502A1 (de) * 1995-06-28 1997-01-02 Merck Patent Gmbh Kappa-Opiatagonisten für entzündliche Darmerkrankungen
DE19531464A1 (de) * 1995-08-26 1997-02-27 Merck Patent Gmbh N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid
WO1998003491A1 (en) * 1996-07-24 1998-01-29 Warner-Lambert Company Diphenyl-cyclopropenes as selective k-agonists
DE19647538A1 (de) * 1996-11-16 1998-05-20 Merck Patent Gmbh Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[1-phenyl-2-(-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid

Also Published As

Publication number Publication date
DE19827633A1 (de) 1999-10-21
ES2375384T3 (es) 2012-02-29
HUP0101600A2 (hu) 2001-09-28
AU2003248428A1 (en) 2003-11-06
HUP0101600A3 (en) 2002-12-28
AR019080A1 (es) 2001-12-26
AU2003248428B2 (en) 2005-10-20
NO317984B1 (no) 2005-01-17
EP1073634A1 (de) 2001-02-07
ATE303361T1 (de) 2005-09-15
AU761721B2 (en) 2003-06-05
EP1073634B1 (de) 2005-08-31
NO20005259D0 (no) 2000-10-19
SI1073634T1 (sl) 2006-02-28
SI1607090T1 (sl) 2012-01-31
CN1310884C (zh) 2007-04-18
HK1039111A1 (en) 2002-04-12
NO20005259L (no) 2000-10-19
PT1607090E (pt) 2012-01-10
DE59912502D1 (de) 2005-10-06
TWI249524B (en) 2006-02-21
CN1846696A (zh) 2006-10-18
CZ20003860A3 (cs) 2001-01-17
US6344566B1 (en) 2002-02-05
CN1297435A (zh) 2001-05-30
ES2251194T3 (es) 2006-04-16
CA2329210A1 (en) 1999-10-28
PL343556A1 (en) 2001-08-27
CY1112314T1 (el) 2015-12-09
SK286442B6 (sk) 2008-10-07
MY120471A (en) 2005-10-31
WO1999054298A1 (de) 1999-10-28
CZ301121B6 (cs) 2009-11-11
CA2329210C (en) 2008-03-04
SK288016B6 (sk) 2012-11-05
AU4031199A (en) 1999-11-08
UA73472C2 (en) 2005-08-15
KR20010042750A (ko) 2001-05-25
DK1607090T3 (da) 2012-01-30
JP4688292B2 (ja) 2011-05-25
KR100649175B1 (ko) 2006-11-24
PL206969B1 (pl) 2010-10-29
EP1607090A1 (de) 2005-12-21
SK15572000A3 (sk) 2001-05-10
ZA200006689B (en) 2002-02-18
EP1607090B1 (de) 2011-10-12
BR9909731A (pt) 2000-12-19
ATE527999T1 (de) 2011-10-15
AR066455A2 (es) 2009-08-19
JP2002512223A (ja) 2002-04-23
RU2298549C2 (ru) 2007-05-10

Similar Documents

Publication Publication Date Title
DK1173431T3 (da) Fremgangsmåde til fremstilling af citalopram
DK1105382T3 (da) Fremgangsmåde til fremstilling af citalopram
DK1159274T3 (da) Fremgangsmåde til fremstilling af citalopram
DK1181272T3 (da) Fremgangsmåde til fremstilling af rent citalopram
DK1181713T3 (da) Fremgangsmåde til fremstilling af rent citalopram
DK1226188T3 (da) Fremgangsmåde til fremstilling af mannichaddukter, som indeholder polyisobutenphenol
DK1032566T3 (da) Fremgangsmåde til fremstilling af citalopram
DK1032565T3 (da) Fremgangsmåde til fremstilling af derivater af taxoid-klassen
DK1038008T3 (da) Fremgangsmåde til fremstilling af EGIII-lignende enzymer
DK1772141T3 (da) Fremgangsmåde til gennemföring af krystallisation i fast tilstand
MA27349A1 (fr) Composition cristalline renfermant de l'escitalopram.
DK0937055T3 (da) Fremgangsmåde til fremstilling af d,I-alfa-tocopherol
DK1309582T3 (da) Fremgangsmåde til fremstilling af citalopram
DK1385826T3 (da) Fremgangsmåde til fremstilling af (S)-(+)- og (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azapin-5-carboxamid
DK1073634T3 (da) Fremgangsmåde til fremstilling af enantiomerrent N-methyl-N[(1S)-1-phenyl-2-2((3S)-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid
BR9603540A (pt) n-metil-n-((1s)-2-((3s)-3-hidróxl-pirrolidin-1-il)etil)-2,2-difenilacetamida
AU5067799A (en) Process for preparing optically pure (s)-3,4-dihydroxybutyric acid derivatives
DK0378455T3 (da) Fremgangsmåde til fremstilling af derivater af (+)-(2S,3S)-3-hydroxy-2-(4-methoxyphenyl)-2,3-dihydro-5H-1,5-benzothiazepine-4-on
DK1296970T3 (da) Fremgangsmåde til fremstilling af citalopram
DK0927766T3 (da) Enzymatisk fremgangsmåde til fremstilling af (S)-cyanhydriner
DK0973769T3 (da) Fremgangsmåde til fremstilling af eprosartan
DK0985733T3 (da) Fremgangsmåde til fremstilling af cyclodextrin
DK1298124T3 (da) Fremgangsmåde til fremstilling af citalopram
DK0906255T3 (da) Fremgangsmåde til fremstilling af enantiomert ren azetidin-2-carboxylsyre
DK0970073T3 (da) Fremgangsmåde til fremstilling af eprosartan